Dhanuka Agritech Q2 & H1 FY26 Earnings Conference Call Transcript
Dhanuka Agritech's Q2 FY26 revenue was ₹598.25 Cr, PAT at ₹93.97 Cr. The company is scaling up Dahej plant production and is awaiting biostimulant clearances. Concall was held on 31st October 2025.
The financial results indicate a decline in revenue and profit compared to the previous year, but new product introductions and expansion plans suggest potential future growth.
The announcement discusses financial results, new product introductions, and operational updates, presenting a balanced view without a strong positive or negative slant.
* Dhanuka Agritech held a conference call on 31st October 2025, to discuss the Un-Audited Financial Results for the Quarter & Half-Year ended on 30th September 2025. * Revenue from operations stood at ₹598.25 crore in Q2 FY26, compared to ₹654.28 crore in Q2 FY25. * EBITDA stood at ₹136.73 crore in Q2 FY26, versus ₹159.58 crore in Q2 FY25. * Profit after tax stood at ₹93.97 crore in Q2 FY26, compared to ₹117.52 crore in Q2 FY25. * The company received the registration certificate of Ipflufenoquin for indigenous manufacture. * Trial production of Difenoconazole has started at the Dahej plant; potential for the Indian market is around 200 metric tons. * Sales of Bifenthrin Technical from Dahej are on track. * Biostimulant 'Wardu' was introduced to enhance the nutrition portfolio; awaiting clearance as per new government guidelines. * Royalty income for Q2 was ₹4.5 crore. * Dahej sales were around ₹22 crore, with a nominal EBITDA loss of ₹46 lakh. * The company expects to start manufacturing Iprovalicarb in India in FY27. * Harsh Dhanuka mentioned that the company is trying for FY '27 EBITDA positive for Dahej scalability.
What to do with a filing like this
Dhanuka Agritech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dhanuka Agritech Limited. Read the original for the full detail.